JP2009543798A5 - - Google Patents

Download PDF

Info

Publication number
JP2009543798A5
JP2009543798A5 JP2009519623A JP2009519623A JP2009543798A5 JP 2009543798 A5 JP2009543798 A5 JP 2009543798A5 JP 2009519623 A JP2009519623 A JP 2009519623A JP 2009519623 A JP2009519623 A JP 2009519623A JP 2009543798 A5 JP2009543798 A5 JP 2009543798A5
Authority
JP
Japan
Prior art keywords
treatment
compounds
inhibition
drugs
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009519623A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009543798A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/073111 external-priority patent/WO2008008747A1/en
Publication of JP2009543798A publication Critical patent/JP2009543798A/ja
Publication of JP2009543798A5 publication Critical patent/JP2009543798A5/ja
Pending legal-status Critical Current

Links

JP2009519623A 2006-07-12 2007-07-10 タンパク質キナーゼ阻害剤としての[4,5’]ビピリミジニル−6,4’−ジアミン誘導体 Pending JP2009543798A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83049206P 2006-07-12 2006-07-12
PCT/US2007/073111 WO2008008747A1 (en) 2006-07-12 2007-07-10 [4,5']bipyrimidinyl-6,4'-diamine derivatives as protein kinase inhbitors

Publications (2)

Publication Number Publication Date
JP2009543798A JP2009543798A (ja) 2009-12-10
JP2009543798A5 true JP2009543798A5 (cg-RX-API-DMAC7.html) 2010-08-26

Family

ID=38617203

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009519623A Pending JP2009543798A (ja) 2006-07-12 2007-07-10 タンパク質キナーゼ阻害剤としての[4,5’]ビピリミジニル−6,4’−ジアミン誘導体

Country Status (21)

Country Link
US (1) US8026243B2 (cg-RX-API-DMAC7.html)
EP (1) EP2044036B1 (cg-RX-API-DMAC7.html)
JP (1) JP2009543798A (cg-RX-API-DMAC7.html)
KR (1) KR20090029832A (cg-RX-API-DMAC7.html)
CN (1) CN101511798B (cg-RX-API-DMAC7.html)
AR (1) AR061867A1 (cg-RX-API-DMAC7.html)
AT (1) ATE508119T1 (cg-RX-API-DMAC7.html)
AU (1) AU2007272646A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0714291A2 (cg-RX-API-DMAC7.html)
CA (1) CA2657381A1 (cg-RX-API-DMAC7.html)
CL (1) CL2007002017A1 (cg-RX-API-DMAC7.html)
DE (1) DE602007014374D1 (cg-RX-API-DMAC7.html)
ES (1) ES2367666T3 (cg-RX-API-DMAC7.html)
MX (1) MX2009000429A (cg-RX-API-DMAC7.html)
PE (1) PE20080548A1 (cg-RX-API-DMAC7.html)
PL (1) PL2044036T3 (cg-RX-API-DMAC7.html)
PT (1) PT2044036E (cg-RX-API-DMAC7.html)
RU (1) RU2009104340A (cg-RX-API-DMAC7.html)
TW (1) TW200811134A (cg-RX-API-DMAC7.html)
UY (1) UY30477A1 (cg-RX-API-DMAC7.html)
WO (1) WO2008008747A1 (cg-RX-API-DMAC7.html)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101679408B (zh) 2006-12-22 2016-04-27 Astex治疗学有限公司 作为fgfr抑制剂的双环杂环化合物
US8131527B1 (en) 2006-12-22 2012-03-06 Astex Therapeutics Ltd. FGFR pharmacophore compounds
JP5442449B2 (ja) 2006-12-22 2014-03-12 アステックス、セラピューティックス、リミテッド 新規化合物
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
EP2308866A1 (de) 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide
WO2011076725A1 (en) 2009-12-21 2011-06-30 Bayer Cropscience Ag Thienylpyri (mi) dinylazole and their use for controlling phytopathogenic fungi
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
AR086992A1 (es) 2011-06-20 2014-02-05 Bayer Ip Gmbh Tienilpiri(mi)dinilpirazoles
IN2014CN02475A (cg-RX-API-DMAC7.html) 2011-10-06 2015-06-19 Bayer Ip Gmbh
UA114490C2 (uk) 2011-10-06 2017-06-26 Байєр Інтеллектуал Проперті Гмбх Гетероциклілпіри(mі)динілпіразоли як фунгіциди
SG11201406584TA (en) 2012-04-24 2014-11-27 Vertex Pharma Dna-pk inhibitors
CA2876689C (en) 2012-06-13 2022-04-26 Incyte Corporation Substituted tricyclic compounds as fgfr inhibitors
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
EA031631B1 (ru) * 2012-09-27 2019-01-31 Чугаи Сеияку Кабушики Каиша Способ лечения или предупреждения злокачественного новообразования, способ отбора пациента, способ тестирования предрасположенности к злокачественному новообразованию у субъекта, гибридный полипептид и его применения
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
AR094812A1 (es) 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
RS62649B1 (sr) 2013-03-12 2021-12-31 Vertex Pharma Inhibitori dnk-pk
PH12015502383B1 (en) 2013-04-19 2023-02-03 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
KR102411227B1 (ko) 2013-10-17 2022-06-21 버텍스 파마슈티칼스 인코포레이티드 Dna-pk 억제제로서 (s)-n-메틸-8-(1-((2'-메틸-[4,5'-비피리미딘]-6-일)아미노)프로판-2-일)퀴놀린-4-카복스아미드 및 이의 듀테로화된 유도체의 공결정
WO2016027781A1 (ja) 2014-08-18 2016-02-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 単環ピリジン誘導体の塩およびその結晶
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CA2976790C (en) 2015-02-20 2024-02-27 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
CN114984013A (zh) 2015-03-25 2022-09-02 国立癌症研究中心 胆管癌治疗剂
AU2016374441B2 (en) 2015-12-17 2021-10-21 Eisai R&D Management Co., Ltd. Therapeutic agent for breast cancer
MX394860B (es) 2016-09-27 2025-03-24 Vertex Pharma Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk).
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
KR102613433B1 (ko) * 2017-10-11 2023-12-13 주식회사 대웅제약 신규한 페닐피리딘 유도체 및 이를 포함하는 약학 조성물
BR112020017922A2 (pt) 2018-03-28 2020-12-22 Eisai R&D Management Co., Ltd. Agente terapêutico para carcinoma hepatocelular
KR102956194B1 (ko) 2018-05-04 2026-04-23 인사이트 코포레이션 Fgfr 억제제의 염
RS66310B1 (sr) 2018-05-04 2025-01-31 Incyte Corp Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
KR102133595B1 (ko) 2019-05-31 2020-07-13 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
KR102112336B1 (ko) 2019-08-12 2020-05-18 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
GEP20247679B (en) 2019-10-14 2024-10-10 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
MX2022006691A (es) 2019-12-04 2022-09-19 Incyte Corp Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr).
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4323405A1 (en) 2021-04-12 2024-02-21 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
TW202313610A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為fgfr抑制劑之三環雜環

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9924862D0 (en) 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
CN102584813B (zh) 2003-05-14 2016-07-06 Ngc药物公司 化合物及其在调节淀粉样蛋白β中的用途
US7189729B2 (en) 2003-09-30 2007-03-13 Irm Llc Methods and compositions as protein kinase inhibitors
EP1751136B1 (en) 2004-05-07 2014-07-02 Amgen Inc. Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
KR20080092412A (ko) 2006-02-06 2008-10-15 아이알엠 엘엘씨 단백질 키나제 억제제로서의 화합물 및 조성물

Similar Documents

Publication Publication Date Title
EA201000341A1 (ru) 2-анилинопурин-8-оны в качестве ингибиторов ttk/mps1 для лечения пролиферативных нарушений
JP6689841B2 (ja) スーパーエンハンサー領域において転写制御を標的とする方法
NO20076561L (no) Imidazoquinoliner som lipid kinaseinhibitorer
MX2021011563A (es) Derivados de 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmaceuticas que los incluyen.
BRPI1014275B8 (pt) composição que compreende partículas de indometacina dispersas em pelo menos dois materiais de moagem parcialmente moídos
CR10419A (es) Derivados de Pirazolo [3,4-D]-Pirimidina útiles para tratar trastornos respiratorios
MX373042B (es) Moleculas para administracion a celulas cancerosas mutantes ros1.
WO2008093075A3 (en) 5,6,7,8-tetrahydropteridine derivatives as hsp90 inhibitors
MX2009004908A (es) Compuestos quimicos.
NO20092737L (no) Substituerte pyrazolo-kinazolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som kinase-inhibitorer
UA99141C2 (ru) Замещенные производные индазола, активные в качестве ингибиторов киназы
MX2009008953A (es) Compuestos como inhibidores de angiogenesis.
MX2009009843A (es) Compuestos espiro sustituidos como inhibidores de la angiogenesis.
WO2010021918A8 (en) Compounds as kinase inhibitors
WO2012034055A3 (en) Compounds as c-met kinase inhibitors
EA201070841A1 (ru) НОВЫЕ ПИРАЗОЛО[3,4-d]ПИРИМИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ПРОТИВОРАКОВЫХ ЛЕКАРСТВЕННЫХ СРЕДСТВ
MX2008013212A (es) 4-anilinquinolina-3-carboxamidas como inhibidores de la cinsa csf-1r.
NZ604983A (en) Dry powder formulation comprising an antimuscarinic drug
WO2012173521A3 (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
WO2007071963A3 (en) Quinazoline derivatives, process for their preparation and their use as anti-cancer agents
NO20074084L (no) Substituerte 4-fenyltetrahydroisokinoliner, fremgangsmate for fremstilling derav, deres anvendelse som medikamenter og medikamenter inneholdende disse
NZ598144A (en) Kinase inhibitors, prodrug forms thereof and their use in therapy
JOP20190052A1 (ar) 5-[2-(بيريدين-2-يلامينو )-3،1 ثيازول-5-يال]-3،2 – ثنائي هيدرو- 1h- إيزوإندول 1--مشتق واحد واستخدامها كمثبطات مزدوجة للدلتا وغاما فوسفاتيديلينوسيتول 3-كيناز
BR112023014825A2 (pt) Forma mórfica cristalina isolada da forma iii do composto a, forma iii do composto a, composição farmacêutica, forma de dosagem sólida, métodos para tratar coronavírus da síndrome respiratória aguda grave 2 e para tratar vírus da hepatite c, uso da forma iii do composto a ou de uma composição farmacêutica ou forma de dosagem sólida, dispersões sólidas seca por pulverização e em camadas granular, e, fabricação de forma iii do composto a
EA201070543A1 (ru) Новые 4-(тетразол-5-ил) хиназолиновые производные в качестве противораковых средств